GE Healthcare announced that its PET imaging agent for Alzheimer’s has been approved for market by the U.S. Food and Drug Administration. Vizamyl (flutemetamol F 18 injection) is used to visually detect beta amyloid plaque, which is associated with Alzheimer’s and dementia, in the brains of patients being evaluated for the conditions.  {read more here}